Barclays
SKYE icon

Barclays’s Skye Bioscience SKYE Stock Holding History

Barclays’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$455 Sell
82
-2,179
-96% -$13.7K ﹤0.01% 5021
2026
Q1 		$11.1K Sell
2,261
-395
-15% -$2.58K ﹤0.01% 4683
2025
Q4 		$15.9K Buy
+2,656
New +$31K ﹤0.01% 4895
2025
Q2 		– Sell
-2,501
Closed -$31.8K – 5604
2025
Q1 		$31.8K Sell
2,501
-6,202
-71% -$135K ﹤0.01% 4709
2024
Q4 		$197K Buy
8,703
+1,467
+20% +$49K ﹤0.01% 4321
2024
Q3 		$226K Buy
7,236
+1,944
+37% +$87.2K ﹤0.01% 4229
2024
Q2 		$339K Buy
+5,292
New +$502K ﹤0.01% 3273

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's SKYE Position: Q2 2026 in Review

Barclays reduced its Skye Bioscience (SKYE) stake by 96% in Q2 2026, selling an estimated $13.7K and leaving 82 shares worth $455. The position accounts for ﹤0.01% of the portfolio, ranked #5021.

Barclays first reported a position in SKYE in Q2 2024 and has held it in 7 quarters since. The position peaked at $339K in Q2 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Barclays held 82 shares of Skye Bioscience worth $455 as of Q2 2026.
  • Barclays sold 2,179 Skye Bioscience shares in Q2 2026, an estimated $13.7K.
  • Skye Bioscience made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5021 holding.
  • Barclays first reported a position in Skye Bioscience in Q2 2024 and has held it in 7 quarters since.
  • Barclays's Skye Bioscience position peaked at $339K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.